JP2007520444A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520444A5 JP2007520444A5 JP2006526316A JP2006526316A JP2007520444A5 JP 2007520444 A5 JP2007520444 A5 JP 2007520444A5 JP 2006526316 A JP2006526316 A JP 2006526316A JP 2006526316 A JP2006526316 A JP 2006526316A JP 2007520444 A5 JP2007520444 A5 JP 2007520444A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- pyridin
- independently selected
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 62
- 150000003839 salts Chemical class 0.000 claims 42
- 125000001424 substituent group Chemical group 0.000 claims 32
- -1 hydroxy, cyano, amino Chemical group 0.000 claims 29
- 229910052736 halogen Inorganic materials 0.000 claims 23
- 150000002367 halogens Chemical class 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 229910052757 nitrogen Inorganic materials 0.000 claims 19
- 150000002431 hydrogen Chemical class 0.000 claims 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 15
- 102000011040 TRPV Cation Channels Human genes 0.000 claims 14
- 108010062740 TRPV Cation Channels Proteins 0.000 claims 14
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 13
- 229910005965 SO 2 Inorganic materials 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 208000002193 Pain Diseases 0.000 claims 9
- 125000002837 carbocyclic group Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 6
- 150000005215 alkyl ethers Chemical class 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 229940124530 sulfonamide Drugs 0.000 claims 4
- 150000003456 sulfonamides Chemical class 0.000 claims 4
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 3
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- FZODJOGHTDQWND-UHFFFAOYSA-N 1-[6-[[2-(methoxymethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]pyrido[2,3-d]pyrimidin-4-yl]amino]-3,3-dimethyl-2h-indol-1-yl]ethanone Chemical compound N=1C2=NC(COC)=NC(NC=3C=C4C(C(CN4C(C)=O)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1C(F)(F)F FZODJOGHTDQWND-UHFFFAOYSA-N 0.000 claims 1
- DDHQDLDEVUBIAJ-UHFFFAOYSA-N 1-[6-[[7-(3-chloropyridin-2-yl)-2-(ethoxymethyl)pyrido[2,3-d]pyrimidin-4-yl]amino]-3,3-dimethyl-2h-indol-1-yl]ethanone Chemical compound N=1C2=NC(COCC)=NC(NC=3C=C4C(C(CN4C(C)=O)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1Cl DDHQDLDEVUBIAJ-UHFFFAOYSA-N 0.000 claims 1
- VZTYUPSGOWLVBU-UHFFFAOYSA-N 2-(2-methylpropoxymethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-n-(1,3,3-trimethyl-2h-indol-6-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC(C)C)=NC(NC=3C=C4C(C(CN4C)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1C(F)(F)F VZTYUPSGOWLVBU-UHFFFAOYSA-N 0.000 claims 1
- IOMOPRNICIERFL-UHFFFAOYSA-N 2-(2-methylpropoxymethyl)-7-pyridin-2-yl-n-(1,3,3-trimethyl-2h-indol-6-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC(C)C)=NC(NC=3C=C4C(C(CN4C)(C)C)=CC=3)=C2C=CC=1C1=CC=CC=N1 IOMOPRNICIERFL-UHFFFAOYSA-N 0.000 claims 1
- QPACYHJNEDJKGO-UHFFFAOYSA-N 2-(2-methylpropoxymethyl)-7-pyridin-2-yl-n-(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC(C)C)=NC(NC=3C=C4C(C(CN(C)C4)(C)C)=CC=3)=C2C=CC=1C1=CC=CC=N1 QPACYHJNEDJKGO-UHFFFAOYSA-N 0.000 claims 1
- QWUYTCGIPVPPBA-UHFFFAOYSA-N 2-(ethoxymethyl)-7-(3-methylpyridin-2-yl)-n-(1,3,3-trimethyl-2h-indol-6-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC)=NC(NC=3C=C4C(C(CN4C)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1C QWUYTCGIPVPPBA-UHFFFAOYSA-N 0.000 claims 1
- ULYHLTQGPSTNIH-UHFFFAOYSA-N 2-(ethoxymethyl)-7-(3-methylpyridin-2-yl)-n-(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC)=NC(NC=3C=C4C(C(CN(C)C4)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1C ULYHLTQGPSTNIH-UHFFFAOYSA-N 0.000 claims 1
- DBHKMBAQFSWZDT-UHFFFAOYSA-N 2-(methoxymethyl)-7-(3-methylpyridin-2-yl)-n-(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COC)=NC(NC=3C=C4C(C(CN(C)C4)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1C DBHKMBAQFSWZDT-UHFFFAOYSA-N 0.000 claims 1
- GPWJOEUJUVTTEP-UHFFFAOYSA-N 2-(methoxymethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-n-(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)-1,8-naphthyridin-4-amine Chemical compound N=1C2=NC(COC)=CC(NC=3C=C4C(C(CN(C)C4)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1C(F)(F)F GPWJOEUJUVTTEP-UHFFFAOYSA-N 0.000 claims 1
- FOUNQNSFZOTUHB-UHFFFAOYSA-N 2-(methoxymethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-n-(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COC)=NC(NC=3C=C4C(C(CN(C)C4)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1C(F)(F)F FOUNQNSFZOTUHB-UHFFFAOYSA-N 0.000 claims 1
- PMUFZJDTZFHGMK-UHFFFAOYSA-N 2-methyl-n-[2-(2-methylpropoxymethyl)-7-(3-methylpyridin-2-yl)pyrido[2,3-d]pyrimidin-4-yl]-1,3-benzoxazol-6-amine Chemical compound N=1C2=NC(COCC(C)C)=NC(NC=3C=C4OC(C)=NC4=CC=3)=C2C=CC=1C1=NC=CC=C1C PMUFZJDTZFHGMK-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- BVHMUENOZZCADF-UHFFFAOYSA-N 4-methyl-n-[2-(2-methylpropoxymethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]pyrido[2,3-d]pyrimidin-4-yl]-2,3-dihydro-1,4-benzoxazin-6-amine Chemical compound N=1C2=NC(COCC(C)C)=NC(NC=3C=C4N(C)CCOC4=CC=3)=C2C=CC=1C1=NC=CC=C1C(F)(F)F BVHMUENOZZCADF-UHFFFAOYSA-N 0.000 claims 1
- LBYNRSNRKHMYOF-UHFFFAOYSA-N 4-methyl-n-[2-(2-methylpropoxymethyl)-7-pyridin-2-ylpyrido[2,3-d]pyrimidin-4-yl]-2,3-dihydro-1,4-benzoxazin-6-amine Chemical compound N=1C2=NC(COCC(C)C)=NC(NC=3C=C4N(C)CCOC4=CC=3)=C2C=CC=1C1=CC=CC=N1 LBYNRSNRKHMYOF-UHFFFAOYSA-N 0.000 claims 1
- BAGYILOEONTUTO-UHFFFAOYSA-N 7-(3-chloropyridin-2-yl)-2-(ethoxymethyl)-n-(1,3,3-trimethyl-2h-indol-6-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC)=NC(NC=3C=C4C(C(CN4C)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1Cl BAGYILOEONTUTO-UHFFFAOYSA-N 0.000 claims 1
- DRNCPHGTYCPFCG-UHFFFAOYSA-N 7-(3-chloropyridin-2-yl)-2-(ethoxymethyl)-n-(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC)=NC(NC=3C=C4C(C(CN(C)C4)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1Cl DRNCPHGTYCPFCG-UHFFFAOYSA-N 0.000 claims 1
- OZDKRWMSINJUKE-UHFFFAOYSA-N 7-(3-chloropyridin-2-yl)-n-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-methylpropoxymethyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC(C)C)=NC(NC=3C=C4OCCOC4=CC=3)=C2C=CC=1C1=NC=CC=C1Cl OZDKRWMSINJUKE-UHFFFAOYSA-N 0.000 claims 1
- NVHCVLVCJQEYRS-UHFFFAOYSA-N 7-(3-chloropyridin-2-yl)-n-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(ethoxymethyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC)=NC(NC=3C=C4OCCOC4=CC=3)=C2C=CC=1C1=NC=CC=C1Cl NVHCVLVCJQEYRS-UHFFFAOYSA-N 0.000 claims 1
- NNGGKNWKQGWMGH-UHFFFAOYSA-N 7-(3-chloropyridin-2-yl)-n-(4,4-dimethyl-2,3-dihydro-1h-quinolin-7-yl)-2-(2-methylpropoxymethyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC(C)C)=NC(NC=3C=C4C(C(CCN4)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1Cl NNGGKNWKQGWMGH-UHFFFAOYSA-N 0.000 claims 1
- DDTLGKAUZLDJMH-UHFFFAOYSA-N 7-(3-chloropyridin-2-yl)-n-(4,4-dimethyl-2,3-dihydro-1h-quinolin-7-yl)-2-(ethoxymethyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC)=NC(NC=3C=C4C(C(CCN4)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1Cl DDTLGKAUZLDJMH-UHFFFAOYSA-N 0.000 claims 1
- PUMFCZFRYZVZSV-UHFFFAOYSA-N 7-(3-chloropyridin-2-yl)-n-(4,4-dimethyl-2,3-dihydro-1h-quinolin-7-yl)-2-(methoxymethyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COC)=NC(NC=3C=C4C(C(CCN4)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1Cl PUMFCZFRYZVZSV-UHFFFAOYSA-N 0.000 claims 1
- MIZKXSZTQLZCEC-UHFFFAOYSA-N 7-[[2-(methoxymethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]pyrido[2,3-d]pyrimidin-4-yl]amino]-2,4,4-trimethylisoquinoline-1,3-dione Chemical compound N=1C2=NC(COC)=NC(NC=3C=C4C(C(C(=O)N(C)C4=O)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1C(F)(F)F MIZKXSZTQLZCEC-UHFFFAOYSA-N 0.000 claims 1
- FWAIOEYXMDPJKZ-UHFFFAOYSA-N 7-[[2-(methoxymethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]pyrido[2,3-d]pyrimidin-4-yl]amino]-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound N=1C2=NC(COC)=NC(NC=3C=C4C(C(CC(=O)N4)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1C(F)(F)F FWAIOEYXMDPJKZ-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 206010006784 Burning sensation Diseases 0.000 claims 1
- 235000002566 Capsicum Nutrition 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000031361 Hiccup Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000006002 Pepper Substances 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 235000016761 Piper aduncum Nutrition 0.000 claims 1
- 235000017804 Piper guineense Nutrition 0.000 claims 1
- 244000203593 Piper nigrum Species 0.000 claims 1
- 235000008184 Piper nigrum Nutrition 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 238000003915 air pollution Methods 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 238000002266 amputation Methods 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 230000002146 bilateral effect Effects 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960002504 capsaicin Drugs 0.000 claims 1
- 235000017663 capsaicin Nutrition 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- GZBREKHQGPDKOG-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-methylpropoxymethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC(C)C)=NC(NC=3C=C4OCCOC4=CC=3)=C2C=CC=1C1=NC=CC=C1C(F)(F)F GZBREKHQGPDKOG-UHFFFAOYSA-N 0.000 claims 1
- JZIKQIVSNQAKKI-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-quinolin-7-yl)-2-(2-methylpropoxymethyl)-7-pyridin-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC(C)C)=NC(NC=3C=C4C(C(CCN4)(C)C)=CC=3)=C2C=CC=1C1=CC=CC=N1 JZIKQIVSNQAKKI-UHFFFAOYSA-N 0.000 claims 1
- FLUJYYWNZMWHEX-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-quinolin-7-yl)-2-(ethoxymethyl)-7-(3-methylpyridin-2-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC)=NC(NC=3C=C4C(C(CCN4)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1C FLUJYYWNZMWHEX-UHFFFAOYSA-N 0.000 claims 1
- POULIGZNZFQFLU-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-quinolin-7-yl)-2-(ethoxymethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COCC)=NC(NC=3C=C4C(C(CCN4)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1C(F)(F)F POULIGZNZFQFLU-UHFFFAOYSA-N 0.000 claims 1
- SPLYKYAMKBNQFF-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-quinolin-7-yl)-2-(methoxymethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=NC(COC)=NC(NC=3C=C4C(C(CCN4)(C)C)=CC=3)=C2C=CC=1C1=NC=CC=C1C(F)(F)F SPLYKYAMKBNQFF-UHFFFAOYSA-N 0.000 claims 1
- FRGRXGJMWKSDCO-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-quinolin-7-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-amine Chemical compound C=1C=C2C(C)(C)CCNC2=CC=1NC(C1=CC=2)=NC=NC1=CC=2C1=NC=CC=C1C(F)(F)F FRGRXGJMWKSDCO-UHFFFAOYSA-N 0.000 claims 1
- PEJKUZWCHOYCTO-UHFFFAOYSA-N n-[2-(ethoxymethyl)-7-(3-methylpyridin-2-yl)pyrido[2,3-d]pyrimidin-4-yl]-4-methyl-2,3-dihydro-1,4-benzoxazin-6-amine Chemical compound N=1C2=NC(COCC)=NC(NC=3C=C4N(C)CCOC4=CC=3)=C2C=CC=1C1=NC=CC=C1C PEJKUZWCHOYCTO-UHFFFAOYSA-N 0.000 claims 1
- SYXVSGUYGDUTHQ-UHFFFAOYSA-N n-[2-(methoxymethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]pyrido[2,3-d]pyrimidin-4-yl]-4-methyl-2,3-dihydro-1,4-benzoxazin-6-amine Chemical compound N=1C2=NC(COC)=NC(NC=3C=C4N(C)CCOC4=CC=3)=C2C=CC=1C1=NC=CC=C1C(F)(F)F SYXVSGUYGDUTHQ-UHFFFAOYSA-N 0.000 claims 1
- RRYULIAQGMYESX-UHFFFAOYSA-N n-[7-(3-chloropyridin-2-yl)-2-(2-methylpropoxymethyl)pyrido[2,3-d]pyrimidin-4-yl]-2-methyl-1,3-benzoxazol-6-amine Chemical compound N=1C2=NC(COCC(C)C)=NC(NC=3C=C4OC(C)=NC4=CC=3)=C2C=CC=1C1=NC=CC=C1Cl RRYULIAQGMYESX-UHFFFAOYSA-N 0.000 claims 1
- GIHVOGUWOOWZCF-UHFFFAOYSA-N n-[7-(3-chloropyridin-2-yl)-2-(2-methylpropoxymethyl)pyrido[2,3-d]pyrimidin-4-yl]-4-methyl-2,3-dihydro-1,4-benzoxazin-6-amine Chemical compound N=1C2=NC(COCC(C)C)=NC(NC=3C=C4N(C)CCOC4=CC=3)=C2C=CC=1C1=NC=CC=C1Cl GIHVOGUWOOWZCF-UHFFFAOYSA-N 0.000 claims 1
- PVBRWUZUBBKQIP-UHFFFAOYSA-N n-[7-(3-chloropyridin-2-yl)-2-(ethoxymethyl)pyrido[2,3-d]pyrimidin-4-yl]-2-methyl-1,3-benzoxazol-6-amine Chemical compound N=1C2=NC(COCC)=NC(NC=3C=C4OC(C)=NC4=CC=3)=C2C=CC=1C1=NC=CC=C1Cl PVBRWUZUBBKQIP-UHFFFAOYSA-N 0.000 claims 1
- 201000009985 neuronitis Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000003491 tear gas Substances 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 0 CC*(C)*C1=C(C)[I-][N+]=CC(*/C2=*\C(\*)=C\CCC(N=C(C=C)N)=C2*C)=C1 Chemical compound CC*(C)*C1=C(C)[I-][N+]=CC(*/C2=*\C(\*)=C\CCC(N=C(C=C)N)=C2*C)=C1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50151503P | 2003-09-09 | 2003-09-09 | |
| US51598403P | 2003-10-31 | 2003-10-31 | |
| PCT/US2004/029583 WO2005023807A2 (en) | 2003-09-09 | 2004-09-09 | 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007520444A JP2007520444A (ja) | 2007-07-26 |
| JP2007520444A5 true JP2007520444A5 (https=) | 2007-11-01 |
Family
ID=34278740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526316A Withdrawn JP2007520444A (ja) | 2003-09-09 | 2004-09-09 | 置換二環式キナゾリン−４−イルアミン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070105865A1 (https=) |
| EP (1) | EP1678173A2 (https=) |
| JP (1) | JP2007520444A (https=) |
| AU (1) | AU2004270740A1 (https=) |
| CA (1) | CA2537883A1 (https=) |
| WO (1) | WO2005023807A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2509233A1 (en) * | 2002-12-13 | 2004-07-01 | Neurogen Corporation | 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
| EP1720542A4 (en) * | 2004-03-04 | 2007-11-28 | Neurogen Corp | ARYL ALKYLAMINO-SUBSTITUTED CHINAZOLINE ANALOGUE |
| JP2007532570A (ja) * | 2004-04-08 | 2007-11-15 | ニューロジェン・コーポレーション | 置換シンノリン−４−イルアミン類 |
| KR101042490B1 (ko) | 2004-07-15 | 2011-06-16 | 니뽄 다바코 산교 가부시키가이샤 | 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제 |
| TW200621251A (en) | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
| US7429608B2 (en) | 2005-01-20 | 2008-09-30 | Amgen Inc. | Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments |
| AU2006208042A1 (en) * | 2005-01-25 | 2006-08-03 | Neurogen Corporation | Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| EP1979348B1 (en) * | 2005-12-21 | 2012-01-18 | Abbott Laboratories | Anti-viral compounds |
| US7915411B2 (en) | 2005-12-21 | 2011-03-29 | Abbott Laboratories | Anti-viral compounds |
| US7906508B2 (en) | 2005-12-28 | 2011-03-15 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity |
| CA2632508A1 (en) * | 2005-12-28 | 2008-06-05 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| WO2008005303A2 (en) * | 2006-06-30 | 2008-01-10 | Janssen Pharmaceutica N.V. | Thiazolopyrimidine modulators of trpv1 |
| US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| WO2008129000A1 (en) * | 2007-04-20 | 2008-10-30 | Novartis Ag | Pyridopyrimidine derivatives and use thereof in the treatment of itch and itch related disorders |
| WO2009078999A1 (en) | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1 |
| MX2013010163A (es) | 2011-03-09 | 2013-10-30 | Merck Patent Gmbh | Derivados de pirido[2,3-b] pirazina y sus usos terapeuticos. |
| US8716297B2 (en) | 2011-07-15 | 2014-05-06 | Abbvie Inc. | Chemical entities to be used for Wee1 inhibition for the treatment of cancer |
| WO2013012915A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| FR2984318B1 (fr) | 2011-12-16 | 2014-06-27 | Oreal | Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines cationiques, composition tinctoriale en comprenant, procedes et utilisations |
| FR2984323B1 (fr) * | 2011-12-16 | 2019-08-30 | L'oreal | Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines, composition tinctoriale en comprenant, procedes et utilisations |
| FR3072286B1 (fr) | 2017-10-13 | 2022-08-12 | Oreal | 7-amino-1,2,3,4-tetrahydroquinoleines particuliers, procede et composition |
| FI4426434T3 (fi) | 2021-11-02 | 2025-11-24 | Flare Therapeutics Inc | Pparg:n käänteisagonisteja ja niiden käyttöjä |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395733B1 (en) * | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| ID19609A (id) * | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
| US6225318B1 (en) * | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| US6413971B1 (en) * | 1996-11-27 | 2002-07-02 | Pfizer Inc | Fused bicyclic pyrimidine derivatives |
| JP2004525071A (ja) * | 2000-07-20 | 2004-08-19 | ニューロジェン コーポレイション | カプサイシン受容体リガンド |
| CN1627944A (zh) * | 2002-01-17 | 2005-06-15 | 神经能质公司 | 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂 |
| CA2509233A1 (en) * | 2002-12-13 | 2004-07-01 | Neurogen Corporation | 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
| TW200510373A (en) * | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
| US7329664B2 (en) * | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
-
2004
- 2004-09-09 JP JP2006526316A patent/JP2007520444A/ja not_active Withdrawn
- 2004-09-09 CA CA002537883A patent/CA2537883A1/en not_active Abandoned
- 2004-09-09 WO PCT/US2004/029583 patent/WO2005023807A2/en not_active Ceased
- 2004-09-09 US US10/571,203 patent/US20070105865A1/en not_active Abandoned
- 2004-09-09 AU AU2004270740A patent/AU2004270740A1/en not_active Abandoned
- 2004-09-09 EP EP04783712A patent/EP1678173A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520444A5 (https=) | ||
| JP6416275B2 (ja) | ヘテロアリールｓｙｋ阻害剤 | |
| JP2022516882A (ja) | Ｍａｔ２ａのアザ複素二環式阻害剤、およびがんの治療のための使用方法 | |
| KR20230137368A (ko) | 암을 치료 및/또는 예방하기 위한 sos1 저해제들의약학적 조합물 | |
| JP2014507417A (ja) | 置換ピリジニル−ピリミジン及び医薬としてのその使用 | |
| CN103827090B (zh) | 取代的喹啉及其作为药物的用途 | |
| WO2023183585A1 (en) | Kras inhibitors | |
| KR102194745B1 (ko) | Ｆａｓｎ 억제용 신규 화합물 및 조성물 | |
| CN1039324C (zh) | 取代的氮杂环并嘧啶化合物,其药用盐或n-氧化物的制备方法 | |
| JP2019196387A (ja) | Ｔｇｆ−ベータ阻害剤としての２，３−二置換ピリジン化合物および使用方法 | |
| ES2649144T3 (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina D1 | |
| AU732863B2 (en) | Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity | |
| KR20220051301A (ko) | Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법 | |
| JP7296408B2 (ja) | Ｍａｌｔ１阻害剤としてのピラゾール誘導体 | |
| KR20150003743A (ko) | 아미노-인돌릴-치환된 이미다졸릴-피리미딘 및 약제로서의 이의 용도 | |
| JP2016532656A (ja) | Ｋｒａｓｇ１２ｃの阻害剤 | |
| NZ568807A (en) | Triazolopyridazines as tyrosine kinase modulators | |
| JP2007509985A5 (https=) | ||
| RS50062B (sr) | Biciklična heterociklična jedinjenja, farmaceutske kompozicije koje sadrže ova jedinjenja i postupci za njihovo pripremanje | |
| BR112015004967A2 (pt) | amino-quinolinas como inibidores de quinase | |
| AU2007338313A1 (en) | Substituted 5H-Pyrimidol[5,4-b]indoles, method for the production thereof, and use thereof for treating non-solid malignant tumors of the blood-producing system | |
| JP2024522184A (ja) | Ｓｅｔｄ２阻害剤との併用療法 | |
| KR20150092301A (ko) | 암, 바이러스성 감염 및 폐질환의 치료를 위한 인돌의 새로운 유도체 | |
| CN115141188A (zh) | 一种取代喹唑啉类化合物、药物组合物及其用途 | |
| JP4596792B2 (ja) | ５−ｈｔ１ａ作動作用と５−ｈｔ３拮抗作用を併有する薬剤 |